Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adhibit is a name associated with two distinct medical products. As a topical dermatological treatment, **Adhibit Gel** contains the retinoid **adapalene** and is indicated for the treatment of mild to moderate acne. It works by binding to specific retinoic acid nuclear receptors, normalizing the differentiation of follicular epithelial cells and providing anti-inflammatory effects. As a surgical product, **Adhibit** was developed by **Angiotech Pharmaceuticals** (and licensed to **Baxter Healthcare**) as a sprayable, self-polymerizing synthetic gel. This formulation is designed to prevent the formation of post-surgical adhesions by creating a temporary physical barrier between tissue surfaces during the healing process.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Adhibit.